Omzet 2024 * | 681 mln. 636 mln. | Omzet 2025 * | 836 mln. 780 mln. | Marktkapitalisatie | 3,26 mld. 3,04 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -109 mln. -102 mln. | Nettowinst (verlies) 2025 * | -6 mln. -5,6 mln. | EV/omzet 2024 * | 4,49 x |
Nettoliquiditeiten 2024 * | 199 mln. 185 mln. | Nettoliquiditeiten 2025 * | 306 mln. 285 mln. | EV/omzet 2025 * | 3,53 x |
K/w-verhouding 2024 * |
-28,2
x | K/w-verhouding 2025 * |
592
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 52,37% |
Recentste transcriptie over HUTCHISON CHINA MED.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Wei Guo Su
CEO | Chief Executive Officer | 66 | 01-01-05 |
Chig Fung Cheng
DFI | Director of Finance/CFO | 57 | 01-07-08 |
Michael Shi
CTO | Chief Tech/Sci/R&D Officer | 59 | 01-01-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chi Keung To
CHM | Chairman | 72 | 01-01-00 |
Graeme Jack
BRD | Director/Board Member | 73 | 01-03-17 |
Dan Eldar
BRD | Director/Board Member | 70 | 01-08-16 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+26,47% | 664 mld. | |
+24,90% | 567 mld. | |
-6,33% | 354 mld. | |
+19,35% | 330 mld. | |
+4,23% | 286 mld. | |
+13,98% | 234 mld. | |
+4,62% | 199 mld. | |
-9,82% | 196 mld. | |
-4,04% | 148 mld. |